Table 4.
Tumor-suppressor miRs upregulated by polyphenols, cell types examined, and effects of miR upregulation.
| miR | CUR | EGCG | GEN | QUE | RES | Effects of miRs Upregulated by Polyphenols on Molecules in the ROS-Mediated Pathway: ↑, Upregulation; ↓ Downregulation |
|---|---|---|---|---|---|---|
| miR-16 |
MCF-7 (breast cancer) (Yang, et al.) [182] |
HepG2 (liver cancer) (Tsang, et al.) [115] |
A549 (lung cancer) (Sonoki, et al.) [116] HSC-6 SCC-9 (oral cancer) (Zhao, et al.) [117] |
MCF7-ADR MCF10A MDA-MB-231-luc-D3H2LN (breast cancer) (Hagiwara, et al.) [118] CCRF-CEM (acute lymphoblastic leukemia) (Azimi, et al.) [119] |
↓Bcl-2 [115,182] | |
| miR-22 | BxPC-3 (pancreatic carcinoma) (Sun, et al.) [120] Y79 (retinoblastoma) (Sreenivasan, et al.) [121] Downregulated * MyLa2059, SeAx (malignant cutaneous lymphoma) (Sibbesen, et al.) [122] |
CNE2 (nasopharyngeal carcinoma) (Li, et al.) [123] |
Tca8113 SAS (oral squamous cell carcinoma) (Zhang, et al.) [124] |
↓VEGF via↓Sp1 [120] | ||
| miR-34a | MDA-MB-231 MDA-MB-435 (breast cancer) (Guo, et al.) [125] SGC-7901 (gastric cancer) (Sun, et al.) [126] HCT116 (colorectal cancer) (Toden, et al.) [127] BxPC-3 (pancreatic cancer) (Sun, et al.) [120] Downregulated * TE-7 (esophageal adenocarcinoma) (Subramaniam, et al.) [128] |
SK-N-BE2 IMR-32 (malignant neuroblastoma) (Chakrabarti, et al.) [129] SH-SY5Y SK-N-DZ (malignant neuroblastoma) (Chakrabarti, et al.) [130] HCT116 HCT116-5FUR (colorectal cancer, 5FU resistant) (Toden, et al.) [131] CNE2 (nasopharyngeal carcinoma) (Li, et al.) [123] HepG2 (hepatocellular carcinoma) (Mostafa, et al.) [132] |
HNC-TICs (tumor-initiating cells of head and neck cancer) (Hsieh, et al.) [133] DU145 (prostate cancer) (Chiyomaru, et al.) [134] AsPC-1 MiaPaCa-2 (pancreatic cancer) (Xia, et al.) [135] |
MDA-MB-231-luc-D3H2LN (breast cancer) (Hagiwara, et al.) [118] DLD-1 (colon cancer) (Kumazaki, et al.) [136] MCF-7 (breast cancer) (Otsuka, et al.) [137] SKOV-3 OV-90 (ovarian cancer) (Yao, et al.) [138] |
↓Bcl-2 [125,126,127,138] ↓NF-κB via Notch-1 [135] |
|
| miR-141 | HCT116-5FUR (colorectal cancer, 5FU resistant) (Toden, et al.) [139] |
Downregulated * MM1.s (multiple myeloma) (Gordon, et al.) [140] |
786-O ACHN (renal carcinoma) (Chiyomaru, et al.) [141] |
MCF7-ADR MCF-7 MCF10A MDA-MB-231-luc-D3H2LN (breast cancer) (Hagiwara, et al.) [118] |
||
| miR-145 | U-87 MG (glioblastoma) Mirgani, et al.) [142] DU145 22RV1 (prostate cancer) (Liu, et al.) [143] |
HCT116 HCT116-5FUR (colorectal cancer, 5FU resistant) (Toden, et al.) [131] |
Y79 (retinoblastoma) (Wei, et al.) [144] |
SKOV-3 A2780 (ovarian cancer) (Zhou, et al.) [145] |
BT-549 MDA-MB-231 MCF-7 (breast cancer) (Sachdeva, et al.) [146] |
↑Caspase-3 [145] |
| miR-146a | U-87 MG (glioblastoma) (Wu, et al.) [31] AsPC-1 (pancreatic cancer) CDF (analog) (Bao, et al.) [147] |
Colo357 Panc-1 (pancreatic cancer) G2535 (mixture of genistein and other isoflavones) (Li, et al.) [148] |
MCF-7 MDA-MB-231 (breast cancer) (Tao, et al.) [26] |
↓NF-κB [31] ↑Caspase-3 [26] ↓EGFR [26] |
||
| miR-200c | HCT116-5FUR SW480-5FUR (colorectal cancer, 5FU resistant) (Toden, et al.) [139] MiaPaCa-2 MiaPaCa-2-GR BxPC-3 (pancreatic cancer) CDF (analog) (Soubani, et al.) [149] |
HCT116-5FUR (colorectal cancer, 5FU resistant) (Toden, et al.) [131] |
Cancer stem cells of nasopharyngeal carcinoma (Shen, et al.) [150] MCF7-ADR MCF-7 MCF10A MDA-MB-231-luc-D3H2LN (breast cancer) (Hagiwara, et al.) [118] HCT116 (colorectal cancer) (Dermani, et al.) [151] |
↑PTEN [149] |
* The items shown in italics are different findings from other reported results (see Text).